PPP1CA

Serine/threonine-protein phosphatase PP1-alpha catalytic subunit · P62136 · PPP1CA on Sugi Atlas →

10,311 patent compounds predicted against PPP1CA, 6,553 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1442223 SCHEMBL1442223 0.62 7/20
SCHEMBL1444745 SCHEMBL1444745 0.52 6/20
SCHEMBL1442705 SCHEMBL1442705 0.46 6/20
SCHEMBL1443064 SCHEMBL1443064 0.60 5/20
SCHEMBL1443569 SCHEMBL1443569 0.58 5/20
SCHEMBL1442979 SCHEMBL1442979 0.56 5/20
SCHEMBL1443370 SCHEMBL1443370 0.53 5/20
SCHEMBL1443372 SCHEMBL1443372 0.53 5/20
SCHEMBL1442188 SCHEMBL1442188 0.53 5/20
SCHEMBL1442022 SCHEMBL1442022 0.50 5/20
SCHEMBL1442346 SCHEMBL1442346 0.49 5/20
SCHEMBL1240241 SCHEMBL1240241 1.00 4/20
SCHEMBL1514562 SCHEMBL1514562 0.82 4/20
SCHEMBL1765058 SCHEMBL1765058 0.77 4/20
SCHEMBL1240684 SCHEMBL1240684 0.72 4/20
SCHEMBL1764895 SCHEMBL1764895 0.72 4/20
SCHEMBL1765068 SCHEMBL1765068 0.71 4/20
SCHEMBL1764890 SCHEMBL1764890 0.69 4/20
SCHEMBL1765006 SCHEMBL1765006 0.69 4/20
SCHEMBL1765071 SCHEMBL1765071 0.67 4/20

Clinical trials — most relevant to PPP1CA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse nanCOMPLETED
Phosphoproteomic Profile of Children With Down Syndrome nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1CA binder may also engage these)

ProteinNameSimilarity
P62138 1.000 P62138 →
P62139 1.000 P62139 →
P62137 1.000 P62137 →
Q8WMS6 1.000 Q8WMS6 →
Q3T0E7 1.000 Q3T0E7 →
P63087 1.000 P63087 →
P36874 1.000 P36874 →
P61287 1.000 P61287 →
P13681 1.000 P13681 →
Q6GQL2 1.000 Q6GQL2 →
P63088 1.000 P63088 →
Q6NVU2 1.000 Q6NVU2 →
PPP1CC Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 1.000 landscape →
P61292 1.000 P61292 →
P62140 1.000 P62140 →
P62143 1.000 P62143 →
P62207 1.000 P62207 →
Q7SZ10 1.000 Q7SZ10 →
P48488 1.000 P48488 →
P22198 1.000 P22198 →
P62141 1.000 P62141 →
P62142 1.000 P62142 →
Q5I085 1.000 Q5I085 →
Q9M9W3 1.000 Q9M9W3 →
Q8MJ46 1.000 Q8MJ46 →
Q3SWW9 1.000 Q3SWW9 →
Q5R740 1.000 Q5R740 →
Q8MJ47 1.000 Q8MJ47 →
P48461 1.000 P48461 →
Q9UW86 1.000 Q9UW86 →